Search results
-
Sino takes out the rest of Merck’s partner
… (LM-108) Anti-CCR8 MAb Pooled ph1/2 data at ASCO 2025: 18% ORR (13/74) in pancreatic cancer + anti-PD-1; …
- 07/18/2025 - 13:28 -
AbbVie steps up for Glenmark's multispecific
… T-cell engager Global ph1 Trignite-1 ; data at ASCO 2025 Unnamed Cellyan Therapeutics …
- 07/14/2025 - 10:23 -
BeOne tries to repeat the inhibitor-degrader double
… BG-68501 showed 6% uORR in 37 solid tumour patients at ASCO 2025 BG-75202 KAT6A/B inhibitor Starting …
- 07/02/2025 - 10:21 -
Exelixis claims a next-generation colorectal win
… Monotx & combos Safety, ORR, PFS, OS Data at ASCO 2025 in 1st-line renal: ORR 63% with zanza + Opdivo …
- 06/24/2025 - 16:17 -
DLL3 goes trispecific
… Zelgen China ph2 data in 3rd-line SCLC presented at ASCO 2025: ORR 63% & 58% with 10mg Q2& mg Q2W respectively …
- 06/20/2025 - 20:42 -
Lyell takes on J&J and Gilead
… in r/r BCL Venue ICML 2025 EHA 2025* ASCO 2025** Setting 3rd-line-plus 2nd-line … RP2D of 2m Car-T cells. Source: company releases, EHA & ASCO 2025. Data also looked good in the second …
- 06/19/2025 - 14:42 -
NextCure joins Merck in an ovarian target
… CUSP06 OnCusp Therapeutics ADC Ph1 US data at ASCO 2025: cORR 20% (5/25) in PROC HS-20124 …
- 06/19/2025 - 11:19 -
More front-line Imdelltra details emerge
… OS Confirmatory trial following AA May 2024; data at ASCO 2025: 40% reduction in risk of death with Imdelltra vs …
- 06/12/2025 - 15:06 -
Merck speeds its KRAS into the colorectal front line
… + chemo combo) to begin Jul 2025 Ph1 Kandlelit-001 at ASCO 2025: ORR 58% (7/12) in 1st-line pts receiving triplet …
- 06/10/2025 - 10:26 -
AbbVie's telisotuzumab conjugate take two
… . This was known to enrol cMet overexpressers, but an ASCO 2025 trials-in-progress poster revealed the precise …
- 06/11/2025 - 14:48
